Summit Clinical Research is proud to announce our participation in the 2025 EASL Congress in Amsterdam, Netherlands, from May 7-10, 2025. As leaders in liver disease research, Summit will present groundbreaking findings focused on Metabolic Dysfunction-Associated Steatohepatitis (MASH), liver fibrosis, and innovative treatment approaches.
Our team, including esteemed scientists and leadership, will showcase cutting-edge research through oral presentations, poster sessions, and a symposium, discussing advancements in MASH, liver fibrosis, and novel non-invasive biomarkers. These presentations reflect Summit’s commitment to advancing the understanding of liver diseases and improving patient outcomes.
What You Can Expect from Summit at EASL 2025:
Oral Presentations:
- Efruxifermin Improves Fibrosis in MASH Cirrhosis Patients (SYMMETRY Trial)
- Sustained Improvements in Biomarkers with Survodutide in MASH and Fibrosis
Poster Presentations:
- Non-invasive Markers to Predict Biopsy Response in MASH and Fibrosis Patients
- General Characteristics of Patients Prescribed Resmetirom
- Resmetirom Treatment Improvements in Liver Stiffness and Fibrosis Biomarkers for MASH Cirrhosis
Symposium:
- Is Liver Biopsy Still Required in Clinical Trials for MetALD and ALD?
Key Topics We’re Focusing On
Our presentations at EASL 2025 will cover a range of critical topics that are transforming the landscape of liver disease research:
- MASH and Fibrosis Treatment: We will delve into promising therapies like survodutide and efruxifermin, which are showing potential in improving liver fibrosis in patients with MASH.
- Non-invasive Biomarkers: We’ll present research on the role of non-invasive markers in predicting biopsy responses, providing alternative methods for monitoring liver disease progression.
- Patient Demographics: Our research includes an analysis of racial and ethnic demographics in MASH clinical trials, shedding light on how diverse patient populations respond to treatments.
Meet Our Leadership
In addition to our scientific team, Brandon Early, President, David Rosa, Director of Business Development, and Michelle Mazuranic, Vice President of the Center of Learning, will be attending the conference. They will be available to discuss Summit’s capabilities in clinical research, patient recruitment, and our innovative approaches to clinical trials in liver disease.
Why Connect with Summit at EASL?
Summit Clinical Research has a long-standing commitment to advancing liver disease research. Our team’s participation in EASL 2025 is an opportunity to engage with industry leaders, share our latest findings, and collaborate on advancing liver health. Whether you’re a researcher, healthcare professional, or industry partner, we welcome the opportunity to connect with you and discuss the latest advancements in clinical research.
If you’re attending EASL 2025, we invite you to schedule a meeting with Brandon, David, or Michelle to learn more about Summit’s work in liver disease research and our role in shaping the future of clinical trials.
Looking Ahead
We are excited to contribute to the conversation at EASL 2025 and look forward to connecting with like-minded professionals who are equally passionate about improving outcomes for patients with liver diseases like MASH. Together, we can continue to drive innovation and make meaningful strides in the fight against liver fibrosis and metabolic liver diseases.
Stay tuned for updates during the conference, and be sure to follow our social media channels for live insights from the event.